National Wealth Management Group LLC Invests $209,000 in United Therapeutics Co. (NASDAQ:UTHR)

National Wealth Management Group LLC bought a new stake in United Therapeutics Co. (NASDAQ:UTHR) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 591 shares of the biotechnology company’s stock, valued at approximately $209,000.

Other large investors have also recently bought and sold shares of the company. Newbridge Financial Services Group Inc. purchased a new stake in shares of United Therapeutics during the fourth quarter worth about $25,000. Millstone Evans Group LLC purchased a new stake in United Therapeutics in the 4th quarter worth approximately $67,000. MassMutual Private Wealth & Trust FSB grew its stake in United Therapeutics by 31.9% in the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 240 shares of the biotechnology company’s stock worth $85,000 after acquiring an additional 58 shares during the period. Jones Financial Companies Lllp lifted its stake in shares of United Therapeutics by 678.9% during the 4th quarter. Jones Financial Companies Lllp now owns 296 shares of the biotechnology company’s stock worth $104,000 after purchasing an additional 258 shares during the period. Finally, SBI Securities Co. Ltd. acquired a new stake in shares of United Therapeutics during the fourth quarter worth $131,000. Institutional investors and hedge funds own 94.08% of the company’s stock.

Insiders Place Their Bets

In related news, COO Michael Benkowitz sold 10,000 shares of United Therapeutics stock in a transaction on Tuesday, January 21st. The shares were sold at an average price of $364.91, for a total value of $3,649,100.00. Following the completion of the sale, the chief operating officer now owns 2,577 shares in the company, valued at approximately $940,373.07. The trade was a 79.51 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Tommy G. Thompson sold 2,500 shares of the stock in a transaction on Monday, March 24th. The shares were sold at an average price of $318.80, for a total transaction of $797,000.00. Following the transaction, the director now owns 8,480 shares in the company, valued at $2,703,424. This trade represents a 22.77 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 72,500 shares of company stock worth $26,134,500 in the last quarter. 11.90% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

UTHR has been the subject of several analyst reports. UBS Group upped their target price on United Therapeutics from $415.00 to $475.00 and gave the company a “buy” rating in a research note on Wednesday, January 8th. StockNews.com downgraded shares of United Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Thursday, February 27th. Finally, HC Wainwright reissued a “buy” rating and issued a $425.00 target price on shares of United Therapeutics in a research report on Thursday, February 27th. One analyst has rated the stock with a sell rating, two have given a hold rating and ten have issued a buy rating to the company’s stock. According to data from MarketBeat, United Therapeutics currently has an average rating of “Moderate Buy” and an average target price of $388.25.

United Therapeutics Price Performance

Shares of NASDAQ UTHR opened at $306.88 on Wednesday. The company has a market capitalization of $13.78 billion, a price-to-earnings ratio of 13.48, a PEG ratio of 0.97 and a beta of 0.64. United Therapeutics Co. has a 1-year low of $225.62 and a 1-year high of $417.82. The business has a 50-day moving average of $337.82 and a 200-day moving average of $355.39.

United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings data on Wednesday, February 26th. The biotechnology company reported $6.19 earnings per share (EPS) for the quarter, beating the consensus estimate of $6.10 by $0.09. United Therapeutics had a net margin of 40.31% and a return on equity of 19.22%. The company had revenue of $735.90 million during the quarter, compared to the consensus estimate of $734.74 million. During the same quarter last year, the company earned $4.36 earnings per share. Research analysts expect that United Therapeutics Co. will post 24.48 EPS for the current fiscal year.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.